These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36255032)

  • 41. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
    Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
    Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors influencing the first and the fifth years adherence to adjuvant endocrine therapy in breast cancer patients in a low income country.
    Nicoletti AP; Damin AP
    Breast Cancer Res Treat; 2024 Apr; 204(3):599-606. PubMed ID: 38225523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors.
    Arch JJ; Crespi CM; Levin ME; Genung SR; Nealis M; Mitchell JL; Bright EE; Albright K; Magidson JF; Stanton AL
    Ann Behav Med; 2022 Aug; 56(8):856-871. PubMed ID: 35323853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
    Bright EE; Finkelstein LB; Nealis MS; Genung SR; Wrigley J; Gu HCJ; Schmiege SJ; Arch JJ
    J Clin Oncol; 2023 Oct; 41(28):4548-4561. PubMed ID: 37531593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
    Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
    Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
    Walsh EA; Post K; Massad K; Horick N; Antoni MH; Penedo FJ; Safren SA; Partridge AH; Peppercorn J; Park ER; Temel JS; Greer JA; Jacobs JM
    Breast Cancer Res Treat; 2024 Apr; 204(3):547-559. PubMed ID: 38231313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis.
    Mausbach BT; Schwab RB; Irwin SA
    Breast Cancer Res Treat; 2015 Jul; 152(2):239-46. PubMed ID: 26077640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
    Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
    Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
    Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Racial and ethnic disparities in post-traumatic stress and illness coherence in breast cancer survivors with comorbid diabetes.
    Mazor M; Wisnivesky JP; Goel M; Harris YT; Lin JJ
    Psychooncology; 2021 Oct; 30(10):1789-1798. PubMed ID: 34109695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
    Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
    J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Racial and ethnic differences in adjuvant hormonal therapy use.
    Livaudais JC; Li C; John EM; Terry MB; Daly M; Buys SS; Habel L; Thompson B; Yanez ND; Coronado GD
    J Womens Health (Larchmt); 2012 Sep; 21(9):950-8. PubMed ID: 22731764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Ziller V; Kalder M; Albert US; Holzhauer W; Ziller M; Wagner U; Hadji P
    Ann Oncol; 2009 Mar; 20(3):431-6. PubMed ID: 19150950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment.
    Green SMC; Hall LH; French DP; Rousseau N; Parbutt C; Walwyn R; Smith SG
    Ann Behav Med; 2023 Oct; 57(11):988-1000. PubMed ID: 37494669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.
    Heiney SP; Truman S; Babatunde OA; Felder TM; Eberth JM; Crouch E; Wickersham KE; Adams SA
    Am J Clin Oncol; 2020 Jul; 43(7):504-509. PubMed ID: 32251120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy.
    Bright EE; Genung SR; Stanton AL; Arch JJ
    Breast Cancer Res Treat; 2022 Oct; 195(3):393-399. PubMed ID: 35962148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.